Insulinoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(→Gender) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | {{CMG}}{{AE}}{{PSD}} | ||
{{Insulinoma}} | {{Insulinoma}} | ||
Revision as of 12:40, 2 October 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Insulinoma epidemiology and demographics |
|
Risk calculators and risk factors for Insulinoma epidemiology and demographics |
Overview
Epidemiology and Demographics
Incidence
- Insulinomas are rare neuroendocrine tumors with an incidence estimated at 1 to 4 new cases per million persons per year.
- Insulinoma is one of the most common types of tumor arising from the islets of Langerhans cells (pancreatic endocrine tumors).
- Estimates of malignancy (metastases) range from 5% to 30%.
- Over 99% of insulinomas originate in the pancreas, with rare cases from ectopic pancreatic tissue.
- About 5% of cases are associated with tumors of the parathyroid glands and the pituitary (Multiple endocrine neoplasia type 1) and are more likely to be multiple and malignant.
- Most insulinomas are small, less than 2 cm.
Age
- The median age at diagnosis is 45.5 years.[1]
Gender
- Females are more commonly affected with insulinoma than males.[1]
- The male to female ratio is approximately 2 to 3.
Race
- There is no racial predilection to the insulinoma.
References
- ↑ 1.0 1.1 Vázquez Quintana E (2004). "The surgical management of insulinoma". Bol Asoc Med P R. 96 (1): 33–8. PMID 15575328.